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NEOPLASIA
Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the
antileukemic drug arsenic trioxide via glutathione depletion and increased
peroxide accumulation in myeloid leukemia cells
Adria´n M. Ramos, Carlos Ferna´ndez, Donna Amra´n, Patricia Sancho, Elena de Blas, and Patricio Aller
Treatment for 14 to 24 hours with low
concentrations of arsenic trioxide (As2O3,
1-4 M) caused apoptosis in U-937
promonocytes and other human myeloid
leukemia cell lines (HL-60, NB4). This
effect was potentiated by cotreatment with
the phosphatidylinositol 3-kinase (PI3K)
inhibitors LY294002 and wortmannin, and
the Akt inhibitor Akti5. However, the inhibi-
tors did not increase the toxicity of the
mitochondria-targeting drug lonidamine,
and the DNA-specific drugs camptoth-
ecin and cisplatin, when used under simi-
lar experimental conditions as As2O3. The
potentiation of As2O3-provoked apopto-
sis involved the increased disruption of
mitochondrial transmembrane potential,
increased caspase-3 activation and cyto-
chrome c release from mitochondria, in-
creased Bax and Bid activation, and at-
tenuation of 27-kDa heat shock protein
(HSP27) expression; the potentiation was
prevented by Bcl-2 overexpression. The
PI3K/Akt inhibitors decreased the intracel-
lular glutathione content, and caused in-
tracellular oxidation, as measured by per-
oxide accumulation. Cotreatment with
subcytotoxic concentrations of hydrogen
peroxide increased apoptosis induction
by As2O3. On the other hand, the treat-
ments did not significantly affect gluta-
thione S-transferase  expression and
activity. These results, which indicate that
glutathione is a target of PI3K/Akt in my-
eloid leukemia cells, may partially explain
the selective increase of As2O3 toxicity by
PI3K/Akt inhibitors, and may provide a
rationale to improve the efficacy of these
inhibitors as therapeutic agents. (Blood.
2005;105:4013-4020)
© 2005 by The American Society of Hematology
Introduction
Arsenic trioxide (As2O3, ATO) is a clinically effective agent in the
treatment of acute promyelocytic leukemia (APL).1 At physiologi-
cally tolerable concentrations ( 5 M in plasma), As2O3 causes
the degradation of the promyelocytic leukemia–retinoic acid recep-
tor  (PML-RAR) fusion oncoprotein, expressed in the vast
majority of APLs, forcing the cells to terminal differentiation
and/or apoptosis.1,2 Moreover, albeit with lower efficacy, As2O3
also induces apoptosis in tumor cells lacking PML-RAR, includ-
ing other types of leukemia and multiple myeloma, which opens
the possibility for broader clinical application of this compound.1,2
Nevertheless, to be effective, this possibility requires the elabora-
tion of strategies to increase the apoptotic action of As2O3 and to
reduce the drug dosage to physiologically tolerable concentrations.
To date, the glutathione (GSH)–based redox system is the best
known determinant of As2O3 sensitivity.2,3 Thus, the apoptotic
action of As2O3 inversely correlates with the endogenous levels of
GSH or GSH-associated enzymes in different leukemia cell
types4-6; and treatments that experimentally deplete or enhance the
GSH content exacerbate or decrease, respectively, the As2O3
toxicity.4,7 Due to the multiplicity of functions of glutathione,8 this
molecule may modulate drug toxicity by different mechanisms.
This includes the scavenging of reactive oxygen species (ROSs),
the production of which may be stimulated by As2O3,5,9 and the
inactivation/detoxification of As2O3, either by direct binding to
GSH10 or through a reaction catalysed by glutathione S-
transferases.11,12 Hence, the modulation of intracellular GSH level
appears as a promissory tool to regulate the clinical efficacy
of As2O3.
An important aspect of apoptosis regulation is the signaling by
serine/threonine kinases, a broad category of kinases that includes,
among others, the mitogen-activated protein kinases (MAPKs) and
the protein kinase B (PKB, Akt).13 Among the 3 main members of
the MAPK family in mammalian cells, the extracellular signal-
regulated kinases (ERK1/2) are associated to mitogenesis, and as
such are generally considered as antiapoptotic.13,14 In a similar
manner, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is
considered as a critical survival-signaling pathway.15,16 Akt-
mediated phosphorylation may alter the activity of proteins such as
caspase-9, some Bcl-2 family members, and nuclear factor B
(NF-B) and other transcription factors, which trigger or restrain
apoptosis; and PI3K/Akt deregulation may contribute to tumorigen-
esis, metastasis, and resistance to chemotherapy.15,16 For this
reason, the PI3K/Akt signaling pathway represents a promissory
target of therapeutic intervention. Actually, the PI3K inhibitors
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LY294002 and wortmannin were observed to exert antitumor
activity in animal cell models15; and phase 1 and 2 clinical trials
using rapamycin and rapamycin derivatives, which target the Akt
downstream kinase mammalian target of rapamycin (mTOR),
are ongoing.17
Of note, protein kinases and intracellular GSH are not unrelated
factors. Thus, Sordet et al18 reported that the protein kinase C
activator 12-O-tetradecanoylphorbol-13-acetate (TPA) potentiated
the As2O3 toxicity by decreasing GSH content in U-937 human
promonocytic leukemia cells. These observations were corrobo-
rated by us, and we also demonstrated that the TPA-provoked GSH
decrease was apparently mediated by ERK activation.19 In addi-
tion, other authors demonstrated that PI3K inhibitors abrogated the
insulin-provoked increase in GSH levels in rat cardiac myocytes20
and hepatocytes.21 These findings led us to examine whether GSH
may represent a target of PI3K/Akt in myeloid cells, and if so,
whether GSH mediates the changes in viability derived of PI3K/
Akt disruption. The obtained results indicate that pharmacologic
inhibitors of PI3K/Akt cause intracellular GSH depletion, increase
peroxide accumulation, and potentiate the apoptotic action of
As2O3 in a GSH-dependent manner, in U-937 promonocytes and
other myeloid leukemia cell lines.
Materials and methods
Chemicals
All components for cell culture were obtained from Invitrogen (Carlsbad,
CA). Monochlorobimane, dichlorodihydrofluorescein diacetate (H2DCFDA),
and rhodamine 123 (R123) were obtained from Molecular Probes (Eugene,
OR). DAPI (4,6-diamino-2-phenylindole) was obtained from Serva (Heidel-
berg, Germany). The kinase inhibitors PD98059, U0126, SB203580,
SP600125, LY294002, wortmannin, and 1L-6-hydroxymethyl-chiro-
inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate (Akti5); the caspase-
3–specific substrate N-acetyl-Asp-Glu-Val-Asp-P-nitroanilide (Ac-
DEVD-pNA); the caspase inhibitor benzyloxy-carbonyl-Val-Ala-
Asp-fluoromethylketone (Z-VAD-Fmk); and rabbit anti–human glutathione
S-transferase P1-1 polyclonal antibody (pAb) were obtained from Calbio-
chem (Darmstad, Germany). Rabbit polyclonal antibodies against human
Akt, phospho-Akt (Ser473), p44/42 MAPK, and phospho-p44/42 MAPK
(Thr202/Tyr204) were obtained from Cell Signaling Technology (Beverly,
MA). Mouse anti–pigeon cytochrome c monoclonal antibody (mAb) clone
7H8.2C12, mouse anti-Bax mAb clone 6A7, and rabbit anti–rat Bcl-X pAb
were obtained from BD PharMingen (San Diego, CA). Mouse anti–human
Bcl-2 (100) mAb and rabbit anti–human Bax (N-20) pAb were from Santa
Cruz Biotechnology (Santa Cruz, CA). Mouse anti–human 70-kDa heat
shock protein (HSP70) mAb (clone C92F3A-5, which specifically recog-
nizes the stress-inducible form of HSP70) and mouse anti–human HSP27
mAb were obtained from StressGen Biotechnologies (Victoria, BC). All
peroxidase- and fluorescein isothiocyanate (FITC)–conjugated immuno-
globulin G (IgG) antibodies were obtained from DAKO Diagno´sticos
(Barcelona, Spain). All other reagents were from Sigma (Madrid, Spain).
Cells and treatments
The human leukemia cell lines U-937 (promonocytic),22 HL-60 (myelomono-
cytic),23 and NB4 (acute promyelocytic)24; and Bcl-2–transfected U-937
cells (U4 clone, kindly provided by Dr Jacqueline Bre´ard, Institut National
de la Sante´ et de la Recherche Me´dicale [INSERM] 461, Chatenay Malabry,
France)25 were routinely grown in RPMI 1640 supplemented with 10%
(vol/vol) heat-inactivated calf serum, 0.2% sodium bicarbonate, and
antibiotics in a humidified 5% CO2 atmosphere at 37°C. For experiments,
16 to 24 hours before the initiation of the treatments the cell concentration
was adjusted at approximately 105 cells/mL. Stock solutions of TPA (20
mM), camptothecin (10 mM), PD98059 (20 mM), U0126 (2.63 mM),
SB203580 (20 mM), SP600125 (20 mM), LY294002 (20 mM), wortmannin
(1 mM), Akti5 (20 mM), Z-VAD-Fmk (25 mM), monochlorobimane (200
mM), Ac-DEVD-pNA (5 mM), N-acetyl-L-cysteine (NAC, 3 M), and
lonidamine (100 mM) were prepared in dimethyl sulfoxide; a stock solution
of cis-platinum(II)-diammine dichloride (cisplatin, 3.3 mM) was prepared
in distilled water; and a stock solution of H2DCFDA (5 mM) was prepared
in ethanol. All of these solutions were stored at 20°C. Stock solutions of
DAPI (10 g/mL), propidium iodide (PI, 1 mg/mL), and R123 (1 mg/mL)
were prepared in phosphate-buffered saline (PBS); and a stock solution of
As2O3 (100 mM) was prepared in distilled water. These solutions were
stored at 4°C. DL-buthionine-S, R-sulfoximine (BSO), and ascorbic acid
(AA) were dissolved in distilled water at 50 and 10 mM, respectively, just
before application.
Flow cytometry
The analysis of samples was carried out using an EPICS XL flow cytometer
(Coulter, Hialeah, FL) equipped with an air-cooled argon laser tuned to 488
nm. The specific fluorescence signals corresponding to FITC, H2DCFDA,
and R123 were collected with a 525-nm band pass filter and the signal
corresponding to PI, with a 620-nm band pass filter.
Determination of apoptosis
Distinctive characteristics of apoptotic cells were the presence of chromatin
condensation/fragmentation and the acquisition of sub-G1 DNA content. To
examine chromatin structure, cells were fixed with ethanol, stained with
DAPI, and examined by fluorescence microscopy. To measure DNA
content, cells were permeabilized, stained with PI, and examined by flow
cytometry. These procedures were described in detail elsewhere.26
Measurement of caspase-3 activity
Samples of 4  106 cells were collected by centrifugation, washed twice
with ice-cold PBS, resuspended in 50 L ice-cold lysis buffer (1 mM
dithiothreitol, 0.03% nonidet P-40 [vol/vol] in 50 mM Tris [tris(hydroxy-
methyl)aminomethane, pH 7.5]), kept on ice for 30 minutes, and finally
centrifuged at 14000g for 15 minutes at 4°C. Samples containing aliquots of
the supernatants (corresponding to 10 g total protein), 8 L caspase
substrate (Ac-DEVD-pNA), and PBS to complete 200 L were prepared in
triplicate in 96-well microtiter plates and incubated for one hour at 37°C.
The absorption was measured by spectrometry at 405 nm.
Determination of active Bax
Cells were fixed with 0.35% (vol/vol) formaldehyde and permeabilized
with 0.1% (wt/vol) saponin in PBS for 5 minutes on ice. After incubation
for 30 minutes at 4°C with anti-Bax antibody clone 6A7, and for 30 minutes
at 4°C with FITC-conjugated anti-IgG antibody, the fluorescence was
estimated by flow cytometry. The 6A7 clone recognizes a NH2-terminal
region of Bax that is occluded under normal conditions, but that is exposed
as a consequence of changes in conformation associated to Bax transloca-
tion to mitochondria in stressed cells.27
Measurement of peroxide accumulation and mitochondrial
transmembrane potential
Intracellular oxidation was measured using the fluorescent probe H2DCFDA,
which is preferentially sensitive to peroxides.28 With this aim, the cells were
collected by centrifugation and incubated for one hour at 37°C in red
phenol–lacking RPMI medium containing 5 M H2DCFDA, centrifuged
again, and resuspended in PBS. The fluorescence was then measured by
flow cytometry.
To measure the mitochondrial transmembrane potential (m), the
cells were incubated for 20 minutes at 37°C with PBS containing 1 g/mL
R123. After washing with PBS, the cells were resuspended in PBS and the
fluorescence was measured by flow cytometry. Under these conditions,
incubation with the depolarizing agent carbonyl cyanide P-(trifluoro-
methoxy) phenylhydrazone (100 M) greatly decreased m.
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Measurement of glutathione content and glutathione
S-transferase  activity
The intracellular reduced glutathione (GSH) content was currently deter-
mined by fluorometry after cell loading with monochlorobimane, following
the previously described procedure.29 In some experiments, the content of
both reduced glutathione (GSH) and glutathione disulfide (GSSG) was
determined by high-pressure liquid chromatography (HPLC), according to
the procedure described by Fariss and Reed,30 using a 5-M Spherisorb
NH2 analytical column (Water, Milford, MA).
The glutathione S-transferase (GST) 	 activity was measured in cell
lysates using 1-chloro-2,4-dinitrobenzene and GSH as substrates,31 accord-
ing to the description of Jing et al.5
Immunoblot assays
To obtain total cellular protein extracts, cells were collected by centrifuga-
tion, washed with PBS, and lysed by 5-minute heating at 100°C followed by
sonication in Laemmli buffer containing a protease inhibitor cocktail, 10
mM sodium fluoride, and 1 mM sodium orthovanadate. To obtain cytosolic
extracts (aimed at determining cytochrome c release from mitochondria),
cells were collected for centrifugation; resuspended in 100 L ice-cold PBS
containing 80 mM KCl, 250 mM sucrose, and 200 g/mL digitonin; and
kept on ice for 5 minutes. After centrifugation (10 000g for 15 minutes at
4°C) the pellet was discarded. Fractions of the total or cytosolic extracts,
containing equal protein amounts, were analyzed by sodium dodecyl sulfate
(SDS)–polyacrylamide gel electrophoresis, blotted onto membranes, and
immunodetected, as previously described.32
Results
Apoptosis induction by As2O3 and other antitumor drugs,
and its modulation by PI3K/Akt inhibitors
First we analyzed the capacity of As2O3, alone or in combination
with the PI3K inhibitors LY294002 and wortmannin, to induce
apoptosis in U-937 cells. LY294002 and wortmannin, which are
known to inhibit PI3K activity with different action mechanisms,15
were used at 30 and 0.5 M, respectively. These concentrations
were adopted on the grounds of earlier publications, and their
efficacy was here corroborated by measuring the level of phosphor-
ylated Akt (Figure 1A, inset). It was observed that As2O3 caused a
concentration-dependent (Figure 1A) and time-dependent (Figure
1B) increase in the frequency of cells with fragmented chromatin,
which is characteristic of apoptosis. Some accumulation of cells at
the G2 phase of the growth cycle was also detected at treatments
longer than 24 hours (result not shown). Treatments for 24 hours
with the PI3K inhibitors alone were innocuous (Figure 1A). Longer
treatments (48-72 hours) did not cause cell death, but decreased
cell proliferation by accumulating cells at the G1 phase of the
growth cycle (result not shown). When used in combination, the
PI3K inhibitors greatly potentiated the generation of apoptosis by
As2O3, with maximum efficacy in the case of LY294002 (Figure
1A-B). These conclusions were confirmed by measuring the
frequency of cells with sub-G1 DNA content (Figure 1C, and
results not shown), which is also an indicator of apoptosis.
Moreover, the pan-caspase inhibitor Z-VAD-Fmk abrogated the
toxicity of As2O3 alone or with LY294002 (Figure 1D), corroborat-
ing that the measured cell death is a bona fide caspase-dependent,
typical apoptosis. The potentiation of As2O3-provoked apoptosis
was also observed using 30 M Akti5, a novel inhibitor that is
known to directly prevent Akt phosphorylation33 (Figure 1A).
To determine whether the potentiation of As2O3 toxicity by
PI3K/Akt inhibitors was a cell line–specific response, experiments
were carried out using human leukemia HL-60 (myelomonocytic)
and NB4 (acute promyelocytic) cells. It was observed that LY294002
also potentiated the apoptotic action of As2O3 in both cell lines
(Figure 1E). NB4 cells exhibited a higher sensitivity to As2O3 than
U-937 and HL-60 cells, as earlier reported.4,5
To determine whether the potentiation of As2O3 toxicity was a
drug-specific response, experiments were carried out using lonid-
amine—an agent that, as As2O3, directly targets the mitochon-
dria34—and the DNA-specific antitumor drugs camptothecin and
Figure 1. Generation of apoptosis by antitumor drugs and PI3K/Akt inhibitors in
human myeloid leukemia cell lines. (A) Frequency of apoptotic cells, as deter-
mined by chromatin fragmentation, in untreated U-937 cell cultures (Cont); in cultures
treated for 24 hours with LY294002 (LY), wortmannin (Wt), or Akti5 alone; and in
cultures treated for 24 hours with the indicated concentrations of As2O3, either alone
(As) or in combination with LY294002 (LY/As), wortmannin (Wt/As), or Akti5
(Akti5/As). The inset represents the relative level of total and phosphorylated Akt
(t-Akt and p-Akt, respectively) in total cellular extracts obtained from untreated cells
(Cont) and cells treated for 24 hours with LY294002 and wortmannin, as determined
by immunoblot. (B) Frequency of apoptosis in U-937 cell cultures treated for the
indicated time periods with 4 M As2O3, alone or in combination with LY294002. (C)
Cell distribution according to their DNA content in untreated U-937 cell cultures (Cont)
and in cultures treated for 24 hours with 4 M As2O3 and LY294002, alone and in
combination. The fraction of cells with sub-G1 DNA content (Ap) is considered as
apoptotic. (D) Frequency of apoptosis in U-937 cell cultures treated for 24 hours with
4 M As2O3, alone or with LY294002, either in the absence () or the presence (
) of
50 M Z-VAD-FMK (Z-VAD). (E) Frequency of apoptosis in human NB4 and HL-60
cell cultures, treated for 24 hours with LY294002 and the indicated concentrations of
As2O3, alone or in combination. (F) Frequency of apoptosis in U-937 cell cultures
treated for 24 hours with the indicated concentrations of lonidamine (Lon), 20 nM
camptothecin (Cpt), and 4 M cisplatin (CDDP), alone () and in combination with
LY294002 or wortmannin. The asterisks indicate significant differences (*P  .02,
**P  .0005, Student t test), in relation to cells treated with the correspondent
antitumor drug alone. LY294002, wortmannin, and Akti5 were used at 30, 0.5, and 30
M, respectively. All agents (antitumor drugs, kinase inhibitors, and Z-VAD-FMK)
were applied simultaneously. The data in panels A-B and D-F represent the mean 
SD of at least 3 determinations. The data in panel C and the inset in panel A are
representative of 2 determinations with similar results.
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cisplatin. For homogeneity, we adopted a similar experimental
design as in the case of As2O3, namely prolonged treatments (24
hours) with relatively low drug concentrations. It was found that,
by contrast to As2O3, the PI3K inhibitors did not modify the
apoptotic action of lonidamine, and they even decreased the
apoptotic action of camptothecin and cisplatin, as measured by
chromatin fragmentation (Figure 1F). This conclusion was corrob-
orated by measuring the frequency of cells with decreased
(sub-G1) DNA content by flow cytometry assays, which also
indicated that camptothecin and cisplatin provoked G2 arrest,
while lonidamine did not cause significant phase-specific block-
ade (results not shown).
Protein kinase activation
It was reported that cytotoxic agents may affect Akt phosphorylation/
activation in U-937 cells.35,36 For this reason, we wanted to
measure Akt phosphorylation upon treatment with As2O3, in the
absence and presence of LY294002. Treatment with As2O3 alone
caused a late decrease (24 hours) in Akt phosphorylation (Figure 2A).
On the other hand, treatment with As2O3 plus LY294002 caused an
earlier decrease in phosphorylation (8 hours and thereafter), with higher
efficacy than treatment with LY294002 alone (Figure 2B).
Earlier publications indicated that PI3K/Akt may negatively
regulate MAPK pathways.37-39 Hence, we queried whether the
potentiation of As2O3 toxicity by PI3K/Akt inhibitors could be
mediated by MAPK activation. To analyze this possibility, experi-
ments were carried out using appropriate MAPK inhibitors, namely
10 M PD98059 and 2.5 M U0126 (specific for mitogen-induced
extracellular kinase [MEK]/ERK), 10 M SB20358 (specific for
p38), and 10 M SP600125 (specific for Jun N-terminal kinase
[JNK]). These concentrations proved to efficaciously block kinase
activation in a preceding work.19 It was found that SB20358 and
SP20358, which were nontoxic when used alone or in combination
with LY294002 (results not shown), did not affect or only
minimally modified the generation of apoptosis by As2O3 plus
LY294002 (Figure 2C), indicating that the potentiation of As2O3
toxicity may not be explained by a possible p38 or JNK activation.
Experiments with MEK/ERK inhibitors could not be carried out
since PD98059 and U0126, although nontoxic when used alone, were
extremely toxic in combination with LY294002, even in the absence of
As2O3 (result not shown). Nonetheless, immunoblot assays revealed that
ERK phosphorylation was not affected by LY294002, either alone or in
combination with As2O3 (Figure 2D), a result that apparently excludes a
possible regulation via the MEK/ERK pathway.
Modulation of mitochondria-related events
It is known that As2O3 directly targets the mitochondria by
interacting with the permeability transition pore.40 This led us to
examine 2 critical mitochondria-associated regulatory events,
namely the dissipation of mitochondrial transmembrane potential
(m) and the release of cytochrome c, which initiates apoptosis
execution along the “intrinsic” pathway.41 Figure 3A shows the
alteration in m, as measured by flow cytometry using the
cationic dye R123. Treatment for 14 hours with As2O3 alone caused
a slight m decrease, which was potentiated by cotreatment with
LY294002. Of note, treatment with the inhibitor alone, although
nontoxic (Figure 1), sufficed to slightly reduce m. Qualitatively
similar results were obtained using the cationic dye 5,5,6,6-
tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide
(JC-1) instead of R123 (results not shown). Figure 3B shows the
release of cytochrome c from mitochondria to the cytosol, as
revealed by immunoblot using cytosolic extracts. As2O3 slightly
induced cytochrome c release, which was greatly potentiated by
cotreatment with LY294002. By contrast to m dissipation, no
cytochrome c release could be detected in cells treated with
LY294002 alone. The changes in cytochrome c location were
followed by the activation of the executioner caspase-3, as
determined by measuring DEVDase activity in cellular extracts.
Thus, extracts from cells treated with As2O3 alone exhibited a
moderate increase in DEVDase activity, which was higher in cells
treated with As2O3 plus LY294002 (Figure 3C). In contrast, the
PI3K inhibitor did not potentiate, and instead decreased, DEVDase
activity in combination with camptothecin or cisplatin, which
agrees with the changes in apoptosis (indicated in Figure 1).
The release of cytochrome c is regulated by proteins of the
Bcl-2 family, which may either inhibit (eg, the antiapoptotic
Figure 2. Akt and ERK activation, and effect of MAPK inhibitors. (A-B) Relative
level of total and phosphorylated Akt in extracts (40 g protein per lane) obtained
from untreated U-937 cells (Cont) and cells treated for the indicated time periods with
4 M As2O3 (A); and from cells treated for the indicated time periods with As2O3 and
LY294002, alone and in combination (B). (C) Frequency of apoptotic cells (mean 
standard deviation of 4 determinations) in cultures treated for 24 hours with 4 M
As2O3, alone or with LY294002, either in the absence () or the presence of 10 M
SP600125 (SP) or 10 M SB203580 (SB). (D) Relative level of total (t-ERK) and
phosphorylated (p-ERK) ERKs in extracts (10 g protein per lane) obtained from
untreated cells and cells treated for the indicated time periods with As2O3 and
LY294002, alone and in combination. All drugs were applied simultaneously. All other
conditions were as in Figure 1.
Figure 3. Disruption of mitochondrial transmembrane potential (m), cyto-
chrome c release, and caspase-3 activation. (A) The figure shows the changes in
m in U-937 cells treated for 14 hours with 4 M As2O3 and LY294002, alone or in
combination, as determined by flow cytometry after cell loading with R123. The
vertical, dotted lines represent the mean fluorescence value in untreated cells (Cont),
to better discern the displacement caused by the treatments. (B) The blot shows the
presence of cytochrome c (Cyt c) in cytosolic extracts (25 g protein per lane)
obtained from untreated cells (Cont), from cells treated for 14 hours with LY291002
alone, and from cells treated for the indicated time periods with 4 M As2O3, alone or
in combination with LY294002. The level of -tubulin (-tub) was also measured as a
control. (C) The figure shows the relative caspase-3 activity, as determined using
Ac-DEVD-pNA as substrate, in extracts from untreated cells (Cont) and cells treated
for 24 hours with 4 M As2O3, 20 nM camptothecin, and 4 M cisplatin, alone () or in
combination with LY294002 (
LY). The results (mean  standard deviation of 3
determinations) are represented in relation to the control, which was given the
arbitrary value of one. All other conditions were as in Figure 1.
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proteins Bcl-2 and Bcl-XL) or promote (eg, the proapoptotic
proteins Bax and Bid) the process.41 Bax remains inactive in the
cytosol, and to be functional requires changes in conformation and
translocation to the mitochondrial membrane.27 Bid is activated by
cleavage followed by translocation to the mitochondrial mem-
brane.42 In addition, the “heat-shock” proteins HSP27 and HSP70
also inhibit apoptosis by blocking cytochrome c and/or other
elements of the intrinsic pathway.43 Hence, experiments were
carried out to measure the expression and modification of these
proteins. The results, represented in Figure 4, were as follows: (1)
Treatment with As2O3, with or without LY294002, did not signifi-
cantly modify the total Bcl-2 and Bax levels, but caused a slight
decrease in Bcl-XL (Figure 4A). (2) As2O3 caused Bax activation,
and this activation was further enhanced by cotreatment with
LY294002, as determined by flow cytometry using the 6A7
antibody. By contrast, the PI3K inhibitor did not potentiate the
camptothecin-provoked Bax activation (Figure 4B). (3) LY294002
also potentiated the As2O3-provoked Bid cleavage, using as
criterion the loss of the 21-kDa proform26 (Figure 4A). (4) As2O3
increased HSP70 and HSP27 expression. However, while HSP70
was not affected by LY294002, the PI3K inhibitor reduced the
basal HSP27 level as well as the increase caused by As2O3 (Figure
4A). Hence, Bax and Bid activation, and HSP27 decrease, may
contribute to the increased cytochrome c release and apoptosis
execution in As2O3 plus LY294002–treated cells. The possible
contribution of Bad, another proapoptotic member of the Bcl-2
family (the activity of which is regulated by Akt-mediated changes
in phosphorylation),16 could not be determined since phosphory-
lated Bad was below detection level in our immunoblot assays.
Finally, it was observed that the frequency of apoptosis was greatly
reduced in Bcl-2–transfected U-937 cells (which, according to our
control observations, possess an 8-fold increase in Bcl-2 content in
relation to the nontransfected cells) (Figure 4C). This indicates that
the generation of apoptosis by As2O3 and its potentiation by
LY294002 is Bcl-2 regulated, as expected in the intrinsic pathway.
Changes in glutathione content
As mentioned in the “Introduction,” the toxicity of As2O3 is greatly
dependent on the intracellular GSH content, which in turn may be
affected by changes in protein kinase activities. For these reasons,
determinations using the GSH-sensitive fluorescent probe monoclo-
robimane were carried out to analyze the possible effects of As2O3
and PI3K/Akt inhibitors on intracellular GSH in U-937 cells. As
indicated in Figure 5A-B, the GSH content was not reduced by
treatment with 1 to 4 M As2O3 alone, but was considerably
decreased by treatment with LY294002, either alone or in combina-
tion with As2O3. This response was corroborated using combina-
tions of As2O3 plus wortmannin or Akti5, and using NB4 and
HL-60 cells instead of U-937 cells (Figure 5B, and results not
shown). The importance of GSH depletion as mediator of apoptosis
Figure 4. Expression and modification of Bcl-2 and HSP family members, and
effect of Bcl-2 overexpression. (A) Relative levels of Bcl-2, Bcl-XL, Bax, Bid
(21-kDa proform), HSP70, HSP27, and -tubulin (used as a control) in total cellular
extracts (15 g per lane) obtained from untreated U-937 cells (Cont), from cells
treated for 14 hours with LY294002 alone, and from cells treated for the indicated time
periods with 4 M As2O3, alone or in combination with LY294002, as determined by
immunoblot. (B) Relative level of activated Bax in untreated cells (Cont), in cells
treated for 14 hours with LY294002 alone, and in cells treated for 14 hours with As2O3
and camptothecin, alone or in the presence of LY294002, as determined by flow
cytometry using the 6A7 antibody. The vertical, dotted lines represent the mean
fluorescence value in the control, to better discern the displacement caused by the
treatments. (C) Frequency of apoptotic cells (mean  standard deviation of 3
determinations) in nontransfected (U-937) and Bcl-2–transfected (U4/Bcl-2) U-937
cell cultures at 24 hours of treatment with 4 M As2O3, alone or in combination with
LY294002. All other conditions were as in Figure 1.
Figure 5. Modulation of GSH level and its relationship with apoptosis. (A-B)
Relative GSH levels, as determined by monochlorobimane derivatization, in U-937
cell cultures treated for 24 hours with LY294002 and the indicated concentrations of
As2O3, alone and in combination (A); and in U-937 and NB4 cell cultures treated for
the indicated time periods with 4 M (U-937) and 2 M (NB4) As2O3 alone, with
LY294002 alone, and with As2O3 plus either LY294002, wortmannin, or Akti5 (B). All
results are expressed in relation to untreated U-937 cell cultures (approximate GSH
content, 9 nmol/106 cells), which received the arbitrary value of one. (C) Frequency of
apoptotic cells in U-937 cell cultures treated for 24 hours with BSO alone, and with
As2O3, camptothecin, cisplatin, and lonidamine, either alone () or in combination
with BSO. (D) Relative GSH levels in U-937 cells treated for 24 hours with LY294002,
with BSO, and with the combination of As2O3 plus either LY294002, TPA, or ascorbic
acid (AA), in the absence () or the presence of NAC (
NAC). (E) Frequency of
apoptotic cells in U-937 cell cultures treated for 24 hours with As2O3 alone, TPA alone,
AA alone, and NAC alone, and with the combinations of As2O3 plus either LY294002,
TPA, or AA, in the absence () or the presence of NAC. BSO, TPA, AA, and NAC
were used at 1 mM, 20 nM, 150 M, and 10 mM, respectively. All drugs were applied
simultaneously. The data represent the means  standard deviation of at least 3
determinations. All other conditions were as in Figure 1.
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induction in our experimental conditions was confirmed using
BSO, a specific inhibitor of -glutamylcysteine synthetase (-
GCS) activity, the rate-limiting enzyme of GSH biosynthesis.
Preliminary determinations indicated that a 24-hour treatment with
1 mM BSO caused approximately a 60% inhibition in the
intracellular GSH content (result not shown). It was observed that
treatment with BSO alone was nontoxic, but as expected cotreat-
ment with BSO increased the apoptotic action of As2O3, in the same
manner as the PI3K/Akt inhibitors. By contrast, BSO failed to
increase the apoptotic action of cisplatin, camptothecin, and
lonidamine (Figure 5C). This result indicates that under the
conditions used here, cisplatin, camptothecin, and lonidamine
behave as GSH-insensitive drugs, and may therefore explain the
inability of the PI3K inhibitors to potentiate their toxicity (Figure 1F).
To shed some light on the mechanisms by which PI3K/Akt
inhibition could deplete GSH, determinations were carried out
using NAC, an agent earlier used as a cysteine donor for GSH
biosynthesis in experiments with As2O3.4,7 In addition to LY294002
and BSO, in these assays we used TPA and AA, which were also
reported to reduce GSH in myeloid cells and other cell sys-
tems.4,7,18,19 The results are indicated in Figure 5D. NAC was
unable to restore the GSH content in cells treated with BSO (which,
as indicated above, blocks enzyme activity); and it was similarly
ineffective in cells treated with LY294002, either alone or with
As2O3. However, NAC restored the GSH content in TPA plus
As2O3– and AA plus As2O3–treated cells. This suggests that, in
contrast to TPA and AA, and in the same manner as BSO, PI3K/Akt
inhibitors modulate GSH biosynthesis at levels other than substrate
availability. Moreover, in good parallelism with these results, NAC
abrogated the increase in toxicity in the case of TPA and AA, but
not in the case of LY294009 (Figure 5E), confirming again the
importance of GSH as a mediator of the increased apoptosis in cells
treated with As2O3 plus PI3K inhibitors.
Final information was obtained by means of HPLC. As
indicated in Table 1, this technique allowed us to corroborate the
capacity of LY294002 to cause GSH depletion, and also proved
that the GSH decrease provoked by the PI3K inhibitor was not
adequately compensated by an increase in GSSG. Nonetheless, the
ratio of GSH to GSSG was diminished, especially in As2O3 plus
LY294002–treated cells, indicating that the treatments caused GSH
oxidation to some degree.
ROS accumulation and GST expression and activity
One of the roles of GSH is the scavenging of ROSs.8 Hence, we
queried whether the GSH depletion derived from PI3K/Akt inhibi-
tion could result in ROS overaccumulation, which might in turn
explain the increase in As2O3 toxicity. To answer this question, flow
cytometry determinations were carried out using the peroxide-
sensitive fluorescent probe H2DCFDA. The results are represented
in Figure 6A: (1) treatment with As2O3 alone, which as indicated in
Figure 5 did not decrease GSH, did not affect peroxide accumula-
tion; (2) treatment with LY294002 alone, which as indicated in
Figures 5 and 1 sufficed to decrease GSH but was not toxic per se,
increased the intracellular peroxide accumulation; and (3) a similar
increase was obtained by treatment with As2O3 plus LY294002,
which as indicated in Figures 5 and 1 decreased GSH and was
highly toxic.
The preceding observations could indicate that while the cells
tolerate a limited ROS overaccumulation without concomitant
toxicity, such overaccumulation may facilitate the generation of
apoptosis by As2O3. To investigate this possibility, experiments
were carried out in which cells were cotreated with As2O3 plus low
H2O2 concentrations (20-40 M), which were per se innocuous or
slightly toxic. In agreement with our hypothesis, H2O2 potentiated
or exerted a synergic effect with As2O3, at the concentrations of 2 to
4 M. By contrast, H2O2 did not modify or exhibited only additive
effects in combination with camptothecin and cisplatin (Figure 6B).
It has been indicated that GST	 is key element in the As2O3
detoxification machinery.11,12 For this reason, we asked whether the
potentiation of As2O3 toxicity by PI3K/Akt inhibitors involved an
alteration in GST	 expression and/or activity. The results in Figure
7 indicate that both the enzyme content (as measured by immuno-
blot assays) and activity remained unaltered or were slightly
increased upon treatment with As2O3 and LY294002, alone and in
combination, when compared with the values in untreated cells.
Discussion
The results in this work indicate that the generation of apoptosis by
low concentrations of As2O3 is potentiated by cotreatment with
PI3K/Akt inhibitors (LY294002, wortmannin, Akti5) in U-937
promonocytic and other myeloid leukemia cells. In spite of the
importance of PI3K/Akt as a survival-promoting pathway, treat-
ment with the inhibitors alone did not significantly cause cell death,
in contrast with the results sometimes obtained in other cell
models.44,45 A possible explanation is that the intact MEK/ERK
pathway provides enough survival signals to keep the cell viability.
In fact, the simultaneous inactivation of PI3K/Akt and MEK/ERKs
by cotreatment with LY294002 plus either PD98059 or U0126
Table 1. Effect of treatment with LY-294002 alone (LY) and LY294002
plus As2O3 (LY/As) on the intracellular GSH and GSSG content
in U-937 cells
Control LY LY/As
No. 6 6 3
GSH, nmol/mg protein 75.1  11.7 45.7  6.1 37.1  6.6
GSSG, nmol/mg protein 1.5  0.4 1.6  0.6 3.1  0.8
GSH/GSSG, nmol/mg protein 50.5 28.6 12.0
The values (nmol/mg protein) were obtained at 24 hours of treatment. For other
conditions, see Figure 1 legend.
Figure 6. Peroxide accumulation and effects of hydrogen peroxide. (A) Intracel-
lular peroxide accumulation in untreated U-937 cells (Cont), in cells treated for 14
hours with LY294002 alone, and in cells treated for 14 hours with 4 M As2O3, alone
or in combination with LY294002, as determined by flow cytometry after cell loading
with H2DCFDA. The vertical, dotted lines represent the mean fluorescence value in
the control, to better discern the displacement caused by the treatments. (B)
Frequency of apoptotic cells (mean standard deviation of at least 4 determinations)
in U-937 cell cultures treated for 24 hours with 20 and 40 M H2O2 alone, and with 1
to 4  As2O3, camptothecin, and cisplatin, either alone () or in combination with
H2O2. All other conditions were as in Figure 1.
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drastically induced apoptosis in U-937 cells. The potentiation by
PI3K/Akt inhibitors of the As2O3-provoked apoptosis represented a
drug-specific response, which could not be reproduced using
lonidamine, camptothecin, and cisplatin. This result was unex-
pected, since with few exceptions PI3K/Akt inhibition was earlier
reported to potentiate the lethality of cytotoxic drugs in myeloid
cells.35,46,47 Such discrepancy might be explained by differences in
the experimental designs used. While other works used elevated
drug concentrations for short time periods (typically 4-6
hours),35,46,47 in the present study we used relatively low concentra-
tions during a longer time period (24 hours). Under these condi-
tions, the alterations of cell cycle regulatory events derived of
PI3K/Akt inhibition may considerably affect the action of the
antitumor drugs, which often behave as cycle phase-specific drugs
(eg, G2-arrest by As2O3, camptothecin, and cisplatin in U-937 cells,
which are p53-null cells48). Actually, this argument was earlier used
to explain the LY294002-provoked attenuation of toxicity upon
long-term cisplatin treatment in 32D murine myeloid cells.49
However, while such explanation might account for the discrepan-
cies between our and other studies, it does not satisfactorily explain
the different modulation by PI3K inhibitors of apoptosis induction
by As2O3 and the other assayed drugs, observed in the present
work. In accordance with its property as a mitochondria-targeting
drug, the action of As2O3 and the potentiation by LY294002
exhibited typical characteristics of the “intrinsic” pathway—
namely increased cytochrome c release, negative regulation by
Bcl-2, and positive regulation by Bax. Moreover, while the
mechanism by which LY294002 inhibits HSP27 expression is still
unknown, such inhibition may also contribute to the increase in
toxicity, since HSP27 is an antiapoptotic protein.43 Nonetheless, the
possibility that the “extrinsic” (receptor-mediated) pathway could
also participate in the process may not be excluded, since As2O3
was reported to activate this pathway in some cell types.50,51 This
possibility is presently under investigation in our laboratory.
In addition, the present results demonstrate that the PI3K/Akt
signaling pathway is required to maintain the normal GSH
metabolism in myeloid cells, since the basal GSH content was
reduced upon treatment with PI3K/Akt inhibitors, either alone or in
combination with As2O3. Although our mechanistic studies on
GSH regulation by PI3K/Akt are still preliminary, it may be
concluded that (1) GSH depletion was not a mere consequence of
cell death, since a 24-hour treatment with LY294002 alone, which
was nontoxic, sufficed to considerably decrease GSH; (2) the GSH
depletion was not adequately compensated by the appearance of
the oxidized form, GSSG; and (3) GSH was not regulated at the
level of substrate availability since (in contrast to TPA and AA, and
in the same manner as BSO) the LY294002-provoked GSH
depletion was not prevented by NAC. Therefore, a possible
explanation is that PI3K/Akt may directly regulate -GCS, either at
the level of enzyme synthesis or activity. Actually, PI3K inhibitors
were recently reported to abrogate the insulin-mediated increase in
-GCS catalytic subunit synthesis in rat hepatocytes,21 and -GCS
activity is susceptible to modulation by changes in phosphoryla-
tion.52 Whatever the mechanism, GSH depletion appears to be an
important factor in explaining the selective potentiation by PI3K/
Akt inhibitors of apoptosis induction by As2O3, but not by other
antitumor drugs. In fact, in contrast to As2O3, under the hereby
assayed conditions, camptothecin, cisplatin, and lonidamine be-
haved as GSH-insensitive drugs, as indicated by the inability of the
GSH-specific agent BSO to increase their toxicity. Due to the
multiplicity of functions of glutathione, it is conceivable that
different mechanisms may participate in potentiating As2O3 toxic-
ity under GSH-depleting conditions. Thus, in our experiments the
LY294002-provoked GSH decrease was paralleled by an increase
in intracellular peroxides. This is important since ROS elevation
has been reported to sensitize leukemic cells to As2O3-provoked
apoptosis53—a response here corroborated by us by cotreatment
with low H2O2 concentrations. In addition, since GSH directly
reacts with As2O3,10 GSH depletion may result in an increase in
free, acting intracellular As2O3 concentration and hence in toxicity,
even in the absence of significant alterations in GST	 expression
and activity. Of course, the GSH-based regulation does not exclude
the concurrence of additional mechanisms (eg, alterations of
critical cell-cycle regulatory events), which as indicated earlier in
this section might explain the unusual attenuation by PI3K
inhibitors of camptothecin and cisplatin toxicity, observed in this
and other reports.49
In summary, the present study provides the first demonstration
that GSH is a target of the PI3K/Akt in myeloid leukemia cells, and
as such it may partially explain the capacity of PI3K/Akt inhibitors
to selectively potentiate the apoptotic action of the antileukemic
drug As2O3. We believe that this property might provide a rationale
to improve the efficacy of therapies based on the use of pharmaco-
logic inhibitors of the PI3K/Akt pathway.
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